Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04158752 · ClinicalTrials.gov registry record · Phase 4
Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
A Phase 4 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT04158752 is a Phase 4 study that has completed, run by Duke University. The registered enrollment target is 26 participants.
The verdict
NCT04158752, a Phase 4 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The investigators will treat patients (targeting enrollment of n=20) who suffer from trigeminal or glossopharyngeal nerve pain in the context of painful small fiber neuropathy. The primary pain-related objective is reduction of pain and reduced use of rescue and other anti-pain medications. Another goal is to monitor and confirm the safety profile established in the migraine population, during previous Phase 3 trials.
Interventions
- DRUG Galcanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-07-24 |
| Est. Completion | 2023-01-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04158752
The ClinicalTrials.gov registry entry for NCT04158752 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Galcanezumab is the first listed.
NCT04158752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04158752 about?
NCT04158752 is a clinical study titled "Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia". The investigators will treat patients (targeting enrollment of n=20) who suffer from trigeminal or glossopharyngeal nerve pain in the context of painful small fiber neuropathy. The primary pain-related objective is reduction of pain and reduced use of rescue and other anti-pain medications. Another ...
What is the current status of trial NCT04158752?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2020-07-24. Estimated completion is 2023-01-04.
What interventions are being tested in trial NCT04158752?
The interventions under investigation include: Galcanezumab (DRUG).
Who is sponsoring clinical trial NCT04158752?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.